NCT07446270尚未招募2 期
A Cohort Clinical Study to Evaluate the Efficacy and Safety of Tunlametinib Combined With Anti-EGFR Monoclonal Antibody in Patients With RAS-mutated Advanced Gastrointestinal Malignancies
Chinese PLA General Hospital0 个研究点目标入组 90 人开始时间: 2026年3月3日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 90
- 主要终点
- ORR
研究概览
简要总结
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signing of written informed consent prior to enrolment;
- •Age > 18 years, males and females eligible;
- •Patients with histologically or pathologically confirmed advanced pancreatic cancer or advanced colorectal cancer who have failed standard therapy;
- •Genetic testing demonstrating RAS mutation;
- •At least one measurable lesion according to RECIST v1.1 assessment;
- •ECOG performance status: 0-1;
- •Expected survival ≥ 3 months;
- •Major organ function meets the following requirements:
- •Haemogram: Neutrophils ≥ 1.5 × 10⁹/L; Platelet count ≥ 90 × 10⁹/L; Haemoglobin ≥ 80 g/L; These haematological parameters must be maintained without the need for G-CSF, platelet or TPO transfusions, blood transfusions, or erythropoietin support therapy 14 days prior to the first dose.
- •Hepatic and renal function: Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula); Total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels ≤ 5 times ULN; Urine protein <2+; if urine protein ≥2+, 24-hour urine protein quantification must show protein ≤1g;
- •Creatine kinase (CK) ≤ 1.5 × ULN
- •Normal coagulation function with no active bleeding or thrombotic disorders: International Normalised Ratio (INR) ≤ 1.5 × ULN; Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN; Prothrombin Time (PT) ≤ 1.5 × ULN;
- •Non-surgically sterilised or female patients of childbearing potential must use one medically approved contraceptive method (e.g., intrauterine device, oral contraceptive, condom) during study treatment and for 3 months post-treatment. Non-surgically sterilised female patients of childbearing potential must have negative serum or urinary hCG tests within 7 days prior to study entry and must not be lactating. Male subjects who are not surgically sterilised or who are of reproductive age must consent to their spouse using a medically approved contraceptive method during the study treatment period and for 3 months after study treatment completion.
- •Able to take oral medication;
- •Subjects must voluntarily participate in this study, demonstrate good compliance, and cooperate with safety and survival follow-up.
排除标准
- •Known contraindications affecting the investigator's choice of therapeutic drug (as per the latest drug information leaflet)
- •Receipt of any other investigational treatment within 4 weeks prior to study dosing initiation;
- •Major surgery (excluding biopsies or minor outpatient procedures such as vascular access placement) or severe trauma within 4 weeks prior to first dosing, or planned major surgery within 30 days after first dosing (as determined by the investigator);
- •Presence of clinically symptomatic third-space effusions (e.g., massive pleural effusion or ascites) that cannot be controlled by drainage or other methods;
- •Symptomatic or untreated brain metastases, meningeal metastases, or spinal cord compression, except for: Asymptomatic brain metastases (i.e., no progressive CNS symptoms attributable to brain lesions, no requirement for corticosteroids or antiepileptic drugs, and imaging confirmation of stable disease for ≥4 weeks); Patients undergoing stereotactic brain radiotherapy or surgery may be eligible if no disease progression is observed in the brain over a period of ≥3 months;
- •Cardiac impairment or clinically significant cardiovascular disease with uncontrolled cardiac symptoms or conditions, such as: (1) NYHA Class II or higher heart failure; (2) unstable angina pectoris; (3) myocardial infarction within the past year; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;
- •History or presence at screening of retinal disease, including: retinal vein occlusion (RVO), retinal artery occlusion, retinal vasculitis, diabetic retinopathy, hypertensive retinopathy, retinal capillaropathy (Costs disease), retinal pigment epithelial detachment (RPED), etc.; Screening for risk factors of RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulable syndromes); retinal diseases such as RPED;
- •Interstitial lung disease or interstitial pneumonia, including patients with clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring intervention);
- •Known active tuberculosis (TB); subjects suspected of active TB requiring clinical investigation to rule out; known active syphilis infection;
- •Human immunodeficiency virus (HIV) antibody positive, syphilis antibody (Anti-TP) positive, hepatitis C virus (HCV) antibody positive with HCV RNA positive, hepatitis B virus surface antigen (HBsAg) positive with HBV DNA positive (HBsAg positive requires further testing for HBV DNA, HBV DNA ≥ 200 IU/ml, or ≥ 10³ copies/ml);
- •History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulators or surgery) within 12 months prior to treatment initiation;
- •Known history of acute or chronic pancreatitis within 6 months prior to study treatment initiation;
- •History of allogeneic bone marrow transplantation or organ transplantation;
- •Uncontrolled active infectious disease requiring intravenous antibiotics, antifungals, or antivirals within 2 weeks prior to first dosing, or unexplained fever >38.5°C during screening/prior to first dosing;
- •Uncorrectable electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia confirmed by serum biochemistry);
- •Past or current neuromuscular disorders associated with elevated CK levels (e.g., inflammatory myopathies, muscular dystrophies, amyotrophic lateral sclerosis, spinal muscular atrophy, rhabdomyolysis syndrome);
- •Arterial or venous thromboembolic events occurring within 6 months prior to first administration, such as cerebrovascular accidents (including transient ischaemic attacks, cerebral haemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;
- •Presence of oesophageal or gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, intra-abdominal abscess, or history of acute gastrointestinal haemorrhage within 6 months prior to first administration; occurrence of hypertensive crisis or hypertensive encephalopathy within 6 months prior to first administration; acute exacerbation of chronic obstructive pulmonary disease within 1 month prior to first administration;
- •Grade 3 bleeding events as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) within 4 weeks prior to first dose;
- •History of severe bleeding tendency or coagulation disorders; screening imaging demonstrating tumour encasement of major vessels or significant necrosis/cavitation where the investigator deems participation may pose a bleeding risk;
- •Current radiographic or clinical evidence of significant gastrointestinal obstruction;
- •Patients with a history of other malignancies within the past five years, except those with completely cured basal cell carcinoma or squamous cell carcinoma of the skin, cervical carcinoma in situ, and/or any malignancy that has been cured with no evidence of disease or at least five consecutive years of disease-free status;
- •Known hypersensitivity to any component of the study drug;
- •History of established neurological or psychiatric disorders, including epilepsy and dementia;
- •Failure of all relevant antineoplastic treatment toxicities to recover to Grade ≤1 (as assessed per NCI CTCAE V5.0) prior to study drug administration;
- •Concurrent use of other antineoplastic agents for concomitant treatment (bisphosphonates for bone metastases are acceptable);
- •Uncontrolled concomitant conditions, including but not limited to severe diabetes mellitus (fasting blood glucose > 250 mg/dl or 13.9 mmol/L) or other serious illnesses requiring systemic treatment;
- •Administration of live or attenuated vaccines within 4 weeks prior to first study dose (Note: If enrolled, subjects must not receive live vaccines during study treatment or within 30 days after the last study dose); ;
- •Positive pregnancy test result in premenopausal female subjects (postmenopausal female subjects must have been amenorrheic for at least 12 months to be considered non-fertile); subjects of reproductive age (including female partners of male subjects) who are likely to become pregnant, are breastfeeding, or are unwilling to use effective contraception during the study period and for at least 30 days after the last dose of study medication;
- •Patients currently receiving intravenous or oral medications that are prohibited by the protocol due to their effects on CYP isoenzymes (strong inducers or inhibitors of CYP2C9 and CYP3A4) and cannot be discontinued at least one week prior to study treatment initiation and throughout the study period; patients taking narrow therapeutic index medications metabolised via CYP1A2;
- •Inability to swallow capsules, or refractory nausea and vomiting, malabsorption, extrahepatic bile diversion, or significant small bowel resection that may impair adequate absorption of the study drug;
- •Other conditions deemed ineligible by the investigator. For example, familial or social factors that may compromise subject safety or the collection of data and samples.
研究组 & 干预措施
Colorectal cancer: Tunlametinib + cetuximab β
Experimental
干预措施: Colorectal cancer: Tunlametinib + cetuximab β (Drug)
Pancreatic cancer: Tunlametinib + cetuximab β
Experimental
干预措施: Pancreatic cancer: Tunlametinib + cetuximab β (Drug)
Pancreatic cancer: Tunlametinib + Nimotuzumab
Experimental
干预措施: Pancreatic cancer: Tunlametinib +Nimotuzumab (Drug)
结局指标
主要结局
ORR
时间窗: 2 years
次要结局
- DOR(2 years)
- OS(2 years)
- AEs(2 years)
- PFS(2 years)
- DCR(2 years)
研究者
Dai, Guanghai
Professor
Chinese PLA General Hospital
相似试验
招募中
2 期
Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-22024-519669-23-00IRCCS Istituto Nazionale Tumori Fondazione Pascale60
尚未招募
1 期
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT07285148Beijing Pearl Biotechnology Limited Liability Company253
招募中
2 期
First line treatment with osimertinib in non-small cell lung cancer, coupled with studies on biological samples.2024-513881-20-00Vestre Viken HF96
尚未招募
不适用
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal MetastasisNCT07348965Guangzhou University of Traditional Chinese Medicine42
招募中
2 期
Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphoma2024-514122-23-00Association International Extranodal Lymphoma Study Group (IELSG)22